{"classes":[{"categories":[{"measurements":[{"comment":"Data for median and upper limit of CI were not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"37.8","upperLimit":"NA","value":"NA"},{"comment":"Data for median and upper limit of CI were not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"12.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"Time from axicabtagene ciloleucel infusion date to the start of the subsequent new lymphoma therapy or death from any cause. KM estimates were used for analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with r/r B-cell iNHL subtype of FL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG000","title":"Axicabtagene Ciloleucel (Follicular Lymphoma)"},{"description":"Participants with r/r B-cell iNHL subtype of MZL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG001","title":"Axicabtagene Ciloleucel (Marginal Zone Lymphoma)"}],"paramType":"MEDIAN","populationDescription":"Participants in the Full Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 85.6 months","title":"Time to Next Therapy","type":"SECONDARY","unitOfMeasure":"months"}